Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

D Russell-Jones, A Vaag, O Schmitz, B K Sethi, N Lalic, S Antic, M Zdravkovic, G M Ravn, R Simó, Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, D Russell-Jones, A Vaag, O Schmitz, B K Sethi, N Lalic, S Antic, M Zdravkovic, G M Ravn, R Simó, Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group

Abstract

Aims/hypothesis: The aim of the study was to compare the efficacy and safety of liraglutide in type 2 diabetes mellitus vs placebo and insulin glargine (A21Gly,B31Arg,B32Arg human insulin), all in combination with metformin and glimepiride.

Methods: This randomised (using a telephone or web-based randomisation system), parallel-group, controlled 26 week trial of 581 patients with type 2 diabetes mellitus on prior monotherapy (HbA(1c) 7.5-10%) and combination therapy (7.0-10%) was conducted in 107 centres in 17 countries. The primary endpoint was HbA(1c). Patients were randomised (2:1:2) to liraglutide 1.8 mg once daily (n = 232), liraglutide placebo (n = 115) and open-label insulin glargine (n = 234), all in combination with metformin (1 g twice daily) and glimepiride (4 mg once daily). Investigators, participants and study monitors were blinded to the treatment status of the liraglutide and placebo groups at all times.

Results: The number of patients analysed as intention to treat were: liraglutide n = 230, placebo n = 114, insulin glargine n = 232. Liraglutide reduced HbA(1c) significantly vs glargine (1.33% vs 1.09%; -0.24% difference, 95% CI 0.08, 0.39; p = 0.0015) and placebo (-1.09% difference, 95% CI 0.90, 1.28; p < 0.0001). There was greater weight loss with liraglutide vs placebo (treatment difference -1.39 kg, 95% CI 2.10, 0.69; p = 0.0001), and vs glargine (treatment difference -3.43 kg, 95% CI 4.00, 2.86; p < 0.0001). Liraglutide reduced systolic BP (-4.0 mmHg) vs glargine (+0.5 mmHg; -4.5 mmHg difference, 95% CI 6.8, -2.2; p = 0.0001) but not vs placebo (p = 0.0791). Rates of hypoglycaemic episodes (major, minor and symptoms only, respectively) were 0.06, 1.2 and 1.0 events/patient/year, respectively, in the liraglutide group (vs 0, 1.3, 1.8 and 0, 1.0, 0.5 with glargine and placebo, respectively). A slightly higher number of adverse events (including nausea at 14%) were reported with liraglutide, but only 9.8% of participants in the group receiving liraglutide developed anti-liraglutide antibodies.

Conclusions/interpretation: Liraglutide added to metformin and sulfonylurea produced significant improvement in glycaemic control and bodyweight compared with placebo and insulin glargine. The difference vs insulin glargine in HbA(1c) was within the predefined non-inferiority margin.

Trial registration: ClinicalTrials.gov NCT00331851.

Funding: The study was funded by Novo Nordisk A/S.

Figures

Fig. 1
Fig. 1
Flow of patients through the study
Fig. 2
Fig. 2
HbA1c (%) over time (last observation carried forward, intention-to-treat population). Liraglutide 1.8 mg (squares); glargine (diamonds); placebo (triangles); *p < 0.05 vs glargine and placebo
Fig. 3
Fig. 3
a Change in bodyweight over time (mean) (last observation carried forward, intention-to-treat population). Liraglutide 1.8 mg (squares); glargine (diamonds); placebo (triangles). b Change in bodyweight from baseline (mean [SD]) (last observation carried forward, intention-to-treat population). *Significant vs glargine (p < 0.0001) and placebo (p = 0.0001)

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1001/jama.281.21.2005', 'is_inner': False, 'url': 'https://doi.org/10.1001/jama.281.21.2005'}, {'type': 'PubMed', 'value': '10359389', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/10359389/'}]}
    2. Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005–2012
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1002/dmrr.328', 'is_inner': False, 'url': 'https://doi.org/10.1002/dmrr.328'}, {'type': 'PubMed', 'value': '12469357', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/12469357/'}]}
    2. Holst JJ (2002) Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 18:430–441
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1152/physrev.00034.2006', 'is_inner': False, 'url': 'https://doi.org/10.1152/physrev.00034.2006'}, {'type': 'PubMed', 'value': '17928588', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/17928588/'}]}
    2. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409–1439
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1358/dnp.2003.16.7.829353', 'is_inner': False, 'url': 'https://doi.org/10.1358/dnp.2003.16.7.829353'}, {'type': 'PubMed', 'value': '14668937', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/14668937/'}]}
    2. Nauck MA, Meier JJ, Creutzfeldt W (2003) Incretins and their analogues as new antidiabetic agents. Drug News Perspect 16:413–422
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1021/jm9909645', 'is_inner': False, 'url': 'https://doi.org/10.1021/jm9909645'}, {'type': 'PubMed', 'value': '10794683', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/10794683/'}]}
    2. Knudsen LB, Nielsen PF, Huusfeldt PO et al (2000) Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 43:1664–1669
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2337/diacare.25.8.1398', 'is_inner': False, 'url': 'https://doi.org/10.2337/diacare.25.8.1398'}, {'type': 'PubMed', 'value': '12145241', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/12145241/'}]}
    2. Elbrønd B, Jakobsen G, Larsen S et al (2002) Pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male patients. Diabetes Care 25:1398–1404
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1007/s00125-001-0719-z', 'is_inner': False, 'url': 'https://doi.org/10.1007/s00125-001-0719-z'}, {'type': 'PubMed', 'value': '11935150', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/11935150/'}]}
    2. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M (2002) The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45:195–202
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2337/diabetes.53.5.1187', 'is_inner': False, 'url': 'https://doi.org/10.2337/diabetes.53.5.1187'}, {'type': 'PubMed', 'value': '15111485', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/15111485/'}]}
    2. Degn KB, Juhl CB, Sturis J et al (2004) One week’s treatment with the long-acting GLP-1 derivative, liraglutide (NN2211), markedly improves 24-h glycemia, alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53:1187–1194
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2337/dc06-2593', 'is_inner': False, 'url': 'https://doi.org/10.2337/dc06-2593'}, {'type': 'PubMed', 'value': '17372153', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/17372153/'}]}
    2. Vilsbøll T, Zdravkovic M, Le-Thi T et al (2007) Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30:1608–1610
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '16230722', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/16230722/'}]}
    2. Heine RJ, Van Gaal L, Johns D, Mihm MJ, Widel MH, Brodows RG, for the GWAA Study Group (2005) Exenatide vs insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 143:559–569
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2337/diacare.28.6.1282', 'is_inner': False, 'url': 'https://doi.org/10.2337/diacare.28.6.1282'}, {'type': 'PubMed', 'value': '15920040', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/15920040/'}]}
    2. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, for the ATLANTUS study group (2005) Improvement of glycemic control in participants with poorly controlled type 2 diabetes: comparison of two algorithms using insulin glargine. Diabetes Care 28:1282–1288
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2337/dc08-S012', 'is_inner': False, 'url': 'https://doi.org/10.2337/dc08-s012'}, {'type': 'PubMed', 'value': '18165335', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/18165335/'}]}
    2. American Diabetes Association (2008) Standards of medical care in diabetes—2008. Diabetes Care 31(Suppl 1):S12–S54
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '17613449', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/17613449/'}]}
    2. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force (2007) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13(Suppl 1):1–66
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2337/diacare.24.4.631', 'is_inner': False, 'url': 'https://doi.org/10.2337/diacare.24.4.631'}, {'type': 'PubMed', 'value': '11315821', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/11315821/'}]}
    2. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB (2001) Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24:631–636
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2337/diacare.23.8.1130', 'is_inner': False, 'url': 'https://doi.org/10.2337/diacare.23.8.1130'}, {'type': 'PubMed', 'value': '10937510', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/10937510/'}]}
    2. Yki-Jarvinen H, Dressler A, Ziemen M (2000) Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 23:1130–1136
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1055/s-2003-39080', 'is_inner': False, 'url': 'https://doi.org/10.1055/s-2003-39080'}, {'type': 'PubMed', 'value': '12734781', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/12734781/'}]}
    2. Massi Benedetti M, Humburg E, Dressler A, Ziemen M (2003) A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 35:189–196
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '12809451', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/12809451/'}]}
    2. Fritsche A, Schweitzer MA, Haring HU (2003) Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 138:952–959
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1089/dia.2005.7.907', 'is_inner': False, 'url': 'https://doi.org/10.1089/dia.2005.7.907'}, {'type': 'PubMed', 'value': '16386096', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/16386096/'}]}
    2. Kennedy L, Herman WH, GOAL A1C Study Team (2005) Glycated hemoglobin assessment in clinical practice: comparison of the A1cNow point-of-care device with central laboratory testing (GOAL A1C Study). Diabetes Technol Ther 7:907–912
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2337/diacare.28.2.254', 'is_inner': False, 'url': 'https://doi.org/10.2337/diacare.28.2.254'}, {'type': 'PubMed', 'value': '15677775', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/15677775/'}]}
    2. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H (2005) Comparison of basal insulin added to oral agents vs twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28:254–259
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2337/diacare.28.2.260', 'is_inner': False, 'url': 'https://doi.org/10.2337/diacare.28.2.260'}, {'type': 'PubMed', 'value': '15677776', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/15677776/'}]}
    2. Raskin P, Allen E, Hollander P et al (2005) Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28:260–265
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2337/diacare.26.11.3080', 'is_inner': False, 'url': 'https://doi.org/10.2337/diacare.26.11.3080'}, {'type': 'PubMed', 'value': '14578243', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/14578243/'}]}
    2. Riddle MC, Rosenstock J, Gerich J (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080–3086
    1. None
    2. Flint A, Kapitza C, Hindsberger C, Zdravkovic M (2008) The once-daily human GLP-1 analogue liraglutide improves both absolute and baseline corrected postprandial glucose levels. Diabetes 57(Suppl 1):A165
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1111/j.1464-5491.2008.02484.x', 'is_inner': False, 'url': 'https://doi.org/10.1111/j.1464-5491.2008.02484.x'}, {'type': 'PMC', 'value': 'PMC2592347', 'is_inner': False, 'url': 'http://www.ncbi.nlm.nih.gov/pmc/articles/pmc2592347/'}, {'type': 'PubMed', 'value': '19183322', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/19183322/'}]}
    2. Courreges JP, Vilsboll T, Zdravkovic M et al (2006) Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med 25:1129–1131
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1210/jc.2003-031403', 'is_inner': False, 'url': 'https://doi.org/10.1210/jc.2003-031403'}, {'type': 'PubMed', 'value': '15181098', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/15181098/'}]}
    2. Gutzwiller JP, Tschopp S, Bock A et al (2004) Glucagon-like peptide 1 induces natriuresis in healthy participants and in insulin-resistant obese men. J Clin Endocrinol Metab 89:3055–3061
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1111/j.1463-1326.2008.00861.x', 'is_inner': False, 'url': 'https://doi.org/10.1111/j.1463-1326.2008.00861.x'}, {'type': 'PubMed', 'value': '18435773', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/18435773/'}]}
    2. Horowitz M, Vilsbøll T, Zdravkovic M, Hammer M, Madsbad S (2008) Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide. Diab Obes Metab 10:593–596
    1. None
    2. Bode B, Hale P, Hammer M, Testa MA, Garber A (2008) Patient reported outcomes in participants with type 2 diabetes treated with monotherapy regimens of once-daily human GLP-1 analogue liraglutide or glimepiride. Diabetologia 51(1):S357 (Abstract 894)
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2337/diacare.27.11.2628', 'is_inner': False, 'url': 'https://doi.org/10.2337/diacare.27.11.2628'}, {'type': 'PubMed', 'value': '15504997', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/15504997/'}]}
    2. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, Exenatide-113 Clinical Study Group (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27:2628–2635
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2337/diacare.28.5.1083', 'is_inner': False, 'url': 'https://doi.org/10.2337/diacare.28.5.1083'}, {'type': 'PubMed', 'value': '15855571', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/15855571/'}]}
    2. Kendall DM, Riddle MC, Rosenstock J et al (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083–1091
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1111/j.1464-5491.2009.02666.x', 'is_inner': False, 'url': 'https://doi.org/10.1111/j.1464-5491.2009.02666.x'}, {'type': 'PMC', 'value': 'PMC2871176', 'is_inner': False, 'url': 'http://www.ncbi.nlm.nih.gov/pmc/articles/pmc2871176/'}, {'type': 'PubMed', 'value': '19317822', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/19317822/'}]}
    2. Marre M, Shaw J, Brandle M et al (2009) Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in participants with type 2 diabetes (LEAD-1 SU). Diabet Med 26:268–278
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2337/db06-0738', 'is_inner': False, 'url': 'https://doi.org/10.2337/db06-0738'}, {'type': 'PubMed', 'value': '17259389', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/17259389/'}]}
    2. de Heer J, Holst JJ (2007) Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 56:438–443

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi